PFS and OS analysis of patients with advanced-stage HL
| . | Univariate analysis . | |||
|---|---|---|---|---|
| 5-year PFS (95% CI) . | P . | 5-year OS (95% CI) . | P . | |
| Age, y | .018 | < .001 | ||
| 0-60 | 64% (52-76) | 83% (67-98) | ||
| > 60 | 35% (11-58) | 48% (26-71) | ||
| 0-44 | 65% (52-78) | .037 | 84% (73-94) | .002 |
| ≥ 45 | 42% (22-62) | 58% (40-76) | ||
| Sex | .83 | .99 | ||
| Male | 57% (43-71) | 74% (60-87) | ||
| Female | 58% (41-75) | 77% (64-89) | ||
| Bulky mass | .91 | .53 | ||
| Yes | 45% (13-76) | 82% (66-99) | ||
| No | 59% (47-71) | 73% (62-84) | ||
| B symptoms | .071 | .15 | ||
| No | 72% (59-86) | 81% (69-93) | ||
| Yes | 43% (27-60) | 69% (55-84) | ||
| ECOG PS | .14 | .039 | ||
| 0-1 | 50% (48-72) | 81% (72-90) | ||
| 2-4 | 43% (15-71) | 41% (5-78) | ||
| IPS | .001 | .007 | ||
| 0-2 | 71% (58-85) | 84% (73-95) | ||
| 3-7 | 40% (23-56) | 66% (52-80) | ||
| Type of treatment | .75 | .86 | ||
| 2-4 cycles | 67% (40-93) | 75% (50-99) | ||
| 6-8 cycles | 56% (44-68) | 75% (65-85) | ||
| RT | .38 | .21 | ||
| Yes | 58% (46-70) | 86% (73-99) | ||
| No | 57% (34-80) | 71% (59-83) | ||
| COX2 stain on RS | .13 | .06 | ||
| Positive | 45% (28-63) | 63% (46-79) | ||
| Negative | 67% (54-80) | 86% (76-95) | ||
| . | Univariate analysis . | |||
|---|---|---|---|---|
| 5-year PFS (95% CI) . | P . | 5-year OS (95% CI) . | P . | |
| Age, y | .018 | < .001 | ||
| 0-60 | 64% (52-76) | 83% (67-98) | ||
| > 60 | 35% (11-58) | 48% (26-71) | ||
| 0-44 | 65% (52-78) | .037 | 84% (73-94) | .002 |
| ≥ 45 | 42% (22-62) | 58% (40-76) | ||
| Sex | .83 | .99 | ||
| Male | 57% (43-71) | 74% (60-87) | ||
| Female | 58% (41-75) | 77% (64-89) | ||
| Bulky mass | .91 | .53 | ||
| Yes | 45% (13-76) | 82% (66-99) | ||
| No | 59% (47-71) | 73% (62-84) | ||
| B symptoms | .071 | .15 | ||
| No | 72% (59-86) | 81% (69-93) | ||
| Yes | 43% (27-60) | 69% (55-84) | ||
| ECOG PS | .14 | .039 | ||
| 0-1 | 50% (48-72) | 81% (72-90) | ||
| 2-4 | 43% (15-71) | 41% (5-78) | ||
| IPS | .001 | .007 | ||
| 0-2 | 71% (58-85) | 84% (73-95) | ||
| 3-7 | 40% (23-56) | 66% (52-80) | ||
| Type of treatment | .75 | .86 | ||
| 2-4 cycles | 67% (40-93) | 75% (50-99) | ||
| 6-8 cycles | 56% (44-68) | 75% (65-85) | ||
| RT | .38 | .21 | ||
| Yes | 58% (46-70) | 86% (73-99) | ||
| No | 57% (34-80) | 71% (59-83) | ||
| COX2 stain on RS | .13 | .06 | ||
| Positive | 45% (28-63) | 63% (46-79) | ||
| Negative | 67% (54-80) | 86% (76-95) | ||
| . | Multivariate analysis . | |||
|---|---|---|---|---|
| PFS . | OS . | |||
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Age > 60 y | — | — | 5.07 (2.20-11.65) | < .001 |
| IPS 3-7 | 2.88 (1.46-5.68) | .002 | — | — |
| ECOG PS > 1 | — | — | 3.38 (1.36-8.45) | .009 |
| . | Multivariate analysis . | |||
|---|---|---|---|---|
| PFS . | OS . | |||
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Age > 60 y | — | — | 5.07 (2.20-11.65) | < .001 |
| IPS 3-7 | 2.88 (1.46-5.68) | .002 | — | — |
| ECOG PS > 1 | — | — | 3.38 (1.36-8.45) | .009 |
— indicates not significant.